Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD

Critical Reviews in Food Science and Nutrition

Volumn 59, Issue 15, 2019, Pages 2494-2505

  Hadi, Amir ^a   Mohammadi, Hamed ^a   Miraghajani, Maryam ^b,c   Ghaedi, Ehsan ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

inflammation; insulin; NAFLD; Synbiotic

Indexed keywords

AMINO ACIDS; ANTHROPOMETRY; CELL DEATH; CHOLESTEROL; INSULIN; LIPOPROTEINS; PLANTS (BOTANY); RANDOM PROCESSES;

HIGH-DENSITY LIPOPROTEIN CHOLESTEROLS; HOMEOSTASIS MODEL ASSESSMENTS; INFLAMMATION; NAFLD; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CLINICAL TRIALS; SYNBIOTIC; TUMOR NECROSIS FACTOR ALPHA;

DISEASES;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SYNBIOTIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ANTHROPOMETRY; BLOOD; BODY MASS; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIETARY SUPPLEMENT; DRUG EFFECT; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; WAIST CIRCUMFERENCE;

ALANINE TRANSAMINASE; ANTHROPOMETRY; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPIDS; NON-ALCOHOLIC FATTY LIVER DISEASE; SYNBIOTICS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE;

EID: 85070876796     PISSN: 10408398     EISSN: 15497852     Source Type: Journal    
DOI: 10.1080/10408398.2018.1458021     Document Type: Review

References (44)

1. Ardalan, M.-R., and H., Nasri. 2014. Lessons from our paleolithic primogenitors; a short look to the world diabetes day 2014 with the theme of “healthy living and diabetes”. Journal of Parathyroid Disease 2:57–58.
2. Asgharian, A., G., Askari, A., Esmailzade, A., Feizi, and V., Mohammadi. 2016. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in Patients with non-alcoholic fatty liver disease: A Clinical Trial. International Journal of Preventive Medicine 7.
3. Asgharian, A., V., Mohammadi, Z., Gholi, A., Esmaillzade, A., Feizi, and G., Askari. 2017. The effect of synbiotic supplementation on body composition and lipid profile in patients with NAFLD: A randomized, double blind, placebo-controlled clinical trial study. Iranian Red Crescent Medical Journal 19.
4. Beltrán-Sánchez, H., M. O., Harhay, M. M., Harhay, and S., McElligott. 2013. Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010. Journal of the American College of Cardiology 62:697–703. doi:10.1016/j.jacc.2013.05.064.
5. Ekhlasi, G., R. K., Mohammadi, S., Agah, M., Zarrati, A. F., Hosseini, S. S. S., Arabshahi, and F., Shidfar. 2016. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. Journal of Research in Medical Sciences 21.
6. Ekhlasi, G., M., Zarrati, S., Agah, A. F., Hosseini, S., Hosseini, S., Shidfar, S. S. S., Aarbshahi, E., Razmpoosh, and F., Shidfar. 2017. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI Journal 16:278.
7. Entezari, M. H., A., Hadi, and M., Kafeshani. 2017. Effects of dietary approaches to stop hypertension diet versus usual dietary advice on glycemic indices in women at risk for cardiovascular disease; a randomized controlled clinical trial. Journal of Renal Injury Prevention 6.
8. Eslamparast, T., H., Poustchi, F., Zamani, M., Sharafkhah, R., Malekzadeh, and A., Hekmatdoost. 2013. The effects of dietary synbiotic supplementation on the liver enzymes, inflammatory markers and hepatic fibrosis in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. Iranian Journal of Nutrition Sciences & Food Technology 8:1–8.
9. Eslamparast, T., H., Poustchi, F., Zamani, M., Sharafkhah, R., Malekzadeh, and A., Hekmatdoost. 2014. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study–. The American Journal of Clinical Nutrition 99:535–42. doi:10.3945/ajcn.113.068890.
10. Fernandes, R., V. A., do Rosario, M. C., Mocellin, M. G., Kuntz, and E. B., Trindade. 2017. Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. Clinical Nutrition 36:1197–206. doi:10.1016/j.clnu.2016.10.003.
11. Ferolla, S. M., C. A., Couto, L., Costa-Silva, G. N., Armiliato, C. A., Pereira, F. S., Martins, M. D. L. A., Ferrari, E. G., Vilela, H. O., Torres, and A. S., Cunha. 2016. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients 8:397. doi:10.3390/nu8070397.
12. Gao, X., Y., Zhu, Y., Wen, G., Liu, and C., Wan. 2016. Efficacy of probiotics in non‐alcoholic fatty liver disease in adult and children: A meta‐analysis of randomized controlled trials. Hepatology Research 46:1226–33. doi:10.1111/hepr.12671.
13. Ghaemi, A., F. A., Taleban, A., Hekmatdoost, A., Rafiei, V., Hosseini, Z., Amiri, R., Homayounfar, and H., Fakheri. 2013. How much weight loss is effective on nonalcoholic fatty liver disease? Hepatitis Monthly 13:e15227. doi:10.5812/hepatmon.15227.
14. Guinane, S., 2013. The effectiveness of probiotics for managing diarrhoea in people with HIV infection: a critically appraised topic. HIV Medicine 14:187–90. doi:10.1111/j.1468-1293.2012.01042.x.
15. Haghighat, L., and N. F., Crum-Cianflone. 2016. The potential risks of probiotics among HIV-infected persons: Bacteraemia due to Lactobacillus acidophilus and review of the literature. International Journal of STD & AIDS 27:1223–30. doi:10.1177/0956462415590725.
16. Hales, C. M., M. D., Carroll, C. D., Fryar, and C. L., Ogden. 2017. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief 1.
17. Houghton, D., C. J., Stewart, C. P., Day, and M., Trenell. 2016. Gut microbiota and lifestyle interventions in NAFLD. International Journal of Molecular Sciences 17:447. doi:10.3390/ijms17040447.
18. Jadad, A. R., R. A., Moore, D., Carroll, C., Jenkinson, D. J. M., Reynolds, D. J., Gavaghan, and H. J., McQuay. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 17:1–12. doi:10.1016/0197-2456(95)00134-4.
19. Javadi, L., M., Ghavami, M., Khoshbaten, A., Safaiyan, A., Barzegari, and B. P., Gargari. 2017a. The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial. Iranian Red Crescent Medical Journal 19.
20. Javadi, L., M., Ghavami, M., Khoshbaten, A., Safaiyan, A., Barzegari, and B. P., Gargari. 2017b. The potential role of probiotics or/and prebiotic on serum lipid profile and insulin resistance in alcoholic fatty liver disease: A double blind randomized clinical trial. Crescent Journal of Medical and Biological Sciences 4:131–38.
21. Khalesi, S., D. W., Johnson, K., Campbell, S., Williams, A., Fenning, S., Saluja, and C., Irwin. 2017. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. European Journal of Clinical Nutrition 1–17.
22. Lavekar, A. S., D. V., Raje, T., Manohar, and A. A., Lavekar. 2017. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian Journal of Hepato-Gastroenterology 7:130. doi:10.5005/jp-journals-10018-1233.
23. Leung, C., L., Rivera, J. B., Furness, and P. W., Angus. 2016. The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology 13:412–25. doi:10.1038/nrgastro.2016.85.
24. Loomba, R., and A. J., Sanyal. 2013. The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology 10:686–90. doi:10.1038/nrgastro.2013.171.
25. Ma, J., Q., Zhou, and H., Li. 2017. Gut microbiota and nonalcoholic fatty liver disease: Insights on mechanisms and therapy. Nutrients 9:1124. doi:10.3390/nu9101124.
26. Ma, Y.-Y., L., Li, C.-H., Yu, Z., Shen, L.-H., Chen, and Y.-M., Li. 2013. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World Journal of Gastroenterology: Wjg 19:6911. doi:10.3748/wjg.v19.i40.6911.
27. Malaguarnera, M., M., Vacante, T., Antic, M., Giordano, G., Chisari, R., Acquaviva, S., Mastrojeni, G., Malaguarnera, A., Mistretta, and G. L., Volti. 2012. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive Diseases and Sciences 57:545–53. doi:10.1007/s10620-011-1887-4.
28. Miraghajani, M., N., Zaghian, M., Mirlohi, A., Feizi, and R., Ghiasvand. 2017a. The impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: A randomized controlled clinical trial. Journal of Renal Nutrition doi:10.1053/j.jrn.2017.04.004.
29. Miraghajani, M., N., Zaghian, M., Mirlohi, and R., Ghiasvand. 2017b. Probiotic soy milk consumption and renal function among type 2 diabetic patients with nephropathy: A randomized controlled clinical trial. Probiotics and Antimicrobial Proteins 1–9.
30. Mofidi, F., H., Poustchi, Z., Yari, B., Nourinayyer, S., Merat, M., Sharafkhah, R., Malekzadeh, and A., Hekmatdoost. 2017. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. British Journal of Nutrition 117:662–68. doi:10.1017/S0007114517000204.
31. Mokhtari, Z., D. L., Gibson, and A., Hekmatdoost. 2017. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr 8:240–52. doi:10.3945/an.116.013151.
32. Nasri, H., 2016. From intestine to kidney; a narrative literature review. Acta Persica Pathophysiologica 1.
33. Rafieian-Kopaei, M., and A., Baradaran. 2012. On the occasion of world diabetes day 2015; act today to change tomorrow. Preventive Medicine 3:747–48.
34. Ruan, Y., J., Sun, J., He, F., Chen, R., Chen, and H., Chen. 2015. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. Plos One 10:e0132121. doi:10.1371/journal.pone.0132121.
35. Sadat Ebrahimi, Z., E., Nasli-Esfahani, A., Nadjarzade, and H., Mozaffari-khosravi. 2017. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. Journal of Diabetes & Metabolic Disorders 16:23. doi:10.1186/s40200-017-0304-8.
36. Sekirov, I., S. L., Russell, L. C. M., Antunes, and B. B., Finlay. 2010. Gut microbiota in health and disease. Physiological Reviews 90:859–904. doi:10.1152/physrev.00045.2009.
37. Shavakhi, A., M., Minakari, H., Firouzian, R., Assali, A., Hekmatdoost, and G., Ferns. 2013. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: A double blind randomized clinical trial. International Journal of Preventive Medicine 4:531–37.
38. Suzuki, A., K., Lindor, J., St Saver, J., Lymp, F., Mendes, A., Muto, T., Okada, and P., Angulo. 2005. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. Journal of Hepatology 43:1060–66. doi:10.1016/j.jhep.2005.06.008.
39. Tabrizi, R., M., Moosazadeh, K. B., Lankarani, M., Akbari, S. T., Heydari, F., Kolahdooz, and Z., Asemi. 2017. The effects of synbiotic supplementation on glucose metabolism and lipid profiles in patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. Probiotics and Antimicrobial Proteins 1–14.
40. Trinchieri, V., L., Laghi, B., Vitali, C., Parolin, I., Giusti, D., Capobianco, P., Mastromarino, and C., De Simone. 2017. efficacy and safety of a Multistrain Probiotic Formulation Depends from Manufacturing. Frontiers in Immunology 8:1474. doi:10.3389/fimmu.2017.01474.
41. Unnikrishnan, R., R., Pradeepa, S. R., Joshi, and V., Mohan. 2017. Type 2 diabetes: demystifying the global epidemic. Diabetes 66:1432–42. doi:10.2337/db16-0766.
42. Woodhouse, C., V., Patel, A., Singanayagam, and D., Shawcross. 2017. the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary Pharmacology & Therapeutics
43. Younossi, Z., Q. M., Anstee, M., Marietti, T., Hardy, L., Henry, M., Eslam, J., George, and E., Bugianesi. 2017. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology doi:10.1038/nrgastro.2017.109.
44. Zhang, Q., Y., Wu, and X., Fei. 2016. Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials. International Journal of Food Sciences and Nutrition 67:571–80. doi:10.1080/09637486.2016.1181156.